Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ: MRNA )

34.06 +0.30 (+0.89%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Moderna, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Arpa Garay Joins Moderna as Chief Commercial Officer
CAMBRIDGE, MA / ACCESSWIRE / April 27, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Arpa Garay will join... 
From Moderna, Inc.
Via AccessWire
Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform
Moderna's first bivalent booster vaccine candidate, mRNA-1273.211, demonstrated superior neutralizing titers compared to mRNA-1273 against all variants of concern, including Omicron; superiority was... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna to Report First Quarter Financial Results on Wednesday, May 4, 2022
CAMBRIDGE, MA / ACCESSWIRE / April 13, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live... 
From Moderna, Inc.
Via AccessWire
Jorge Gomez Joins Moderna as Chief Financial Officer
CAMBRIDGE, MA / ACCESSWIRE / April 11, 2022 / Moderna, Inc., (Nasdaq:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that Jorge Gomez will join... 
From Moderna, Inc.
Via AccessWire
Moderna Announces First Participants Dosed in Phase 1/2 Study with mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccine Candidates
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle CAMBRIDGE, MA / ACCESSWIRE / April... 
From Moderna, Inc.
Via AccessWire
IAVI and Moderna Partner to Tackle Broad Global Health Priorities Using mRNA for Vaccines and Antibodies
Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis NEW YORK, NY and CAMBRIDGE, MA / ACCESSWIRE / April 7, 2022 /... 
From Moderna, Inc.
Via AccessWire
Topics Death
Exposures COVID-19 Death
Moderna Launches New Charitable Foundation
Initial grants of approximately $5 million awarded to local and global nonprofits that support groups and causes disproportionately affected by COVID-19 CAMBRIDGE, MA / ACCESSWIRE / April 4, 2022 /... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna Launches New Charitable Foundation
SOURCE: Moderna 
Via 3BL Media
Moderna Receives FDA Approval for Emergency Use Authorization of 2nd Booster Dose of Its COVID-19 Vaccine, mRNA-1273
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age CAMBRIDGE, MA / ACCESSWIRE / March 29, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
Race to Develop Universal ‘Variant-Proof’ Covid Vaccine Involves Several Players
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2022 – USA News Group – Whenever a new COVID-19 variant emergences, health authorities have had limited options to fight... 
Via FinancialNewsMedia
Exposures COVID-19
Moderna Announces Clinical and Program Updates at 3rd Annual Vaccines Day
- COVID-19 vaccine Phase 2/3 study in children 6 months to under 6 years has successfully met its primary endpoint with robust neutralizing antibody titers similar to adults. Moderna is moving forward... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
Moderna Finalizes Strategic Partnership with Australian Government
On-shore manufacturing facility based in Melbourne, Australia, expected to produce up to 100 million mRNA respiratory vaccine doses annually CAMBRIDGE, MA / ACCESSWIRE / March 23, 2022 / Moderna, Inc.... 
From Moderna, Inc.
Via AccessWire
Moderna Announces its COVID-19 Vaccine Phase 2/3 Study in Children 6 Months to Under 6 Years Has Successfully Met Its Primary Endpoint
- Two 25 μg doses of mRNA-1273 in participants 6 months to under 6 years met primary endpoint with robust neutralizing antibody titers similar to adults mRNA-1273 was generally well tolerated in this... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
Moderna Announces New Development Programs Ahead of 3rd Annual Vaccines Day
mRNA-1230 is a combination respiratory vaccine candidate against SARS-CoV-2 virus, influenza virus and respiratory syncytial virus (RSV) mRNA-1287 is a vaccine candidate against the four endemic human... 
From ModernaTX, Inc
Via AccessWire
Moderna Announces New Supply Agreement for 2023 with Switzerland for Additional Seven Million Doses of Moderna's COVID-19 Booster Vaccine
CAMBRIDGE, MA / ACCESSWIRE / March 21, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a new supply agreement with... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna Submits Amendment to the Emergency Use Authorization for an Additional Booster Dose of its COVID-19 Vaccine in the U.S.
CAMBRIDGE, MA / ACCESSWIRE / March 17, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has submitted a... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
Health Canada Authorizes Moderna's COVID-19 Vaccine in Children (6-11 Years)
Announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna and the Japanese Government Reach an Agreement to Supply Japan with Additional 70 Million Doses of Moderna's COVID-19 Booster Vaccine
CAMBRIDGE, MA / ACCESSWIRE / March 16, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement with the... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna Announces First Participant Dosed in Phase 1 Study of its HIV Trimer mRNA Vaccine
CAMBRIDGE, MA / ACCESSWIRE / March 14, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant... 
From Moderna, Inc.
Via AccessWire
Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Bivalent Booster Candidate
Moderna's Omicron-specific bivalent booster candidate (mRNA-1273.214) combines Moderna's Omicron-specific booster candidate (mRNA-1273.529) and the Moderna COVID-19 vaccine (mRNA-1273) Moderna expects... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna to Host Third Annual Virtual Vaccines Day on March 24, 2022
CAMBRIDGE, MA / ACCESSWIRE / March 10, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host its... 
From Moderna, Inc.
Via AccessWire
Moderna Announces Its Global Public Health Strategy
Moderna announces commitment to advance vaccines targeting 15 pathogens identified as biggest public health risk by WHO and CEPI into clinical studies by 2025 Moderna launches mRNA Access, a new... 
From Moderna, Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Moderna Announces Memorandum of Understanding with the Government of the Republic of Kenya to Establish its First mRNA Manufacturing Facility in Africa
Facility to manufacture drug substance with opportunity for fill/finish and packaging capabilities Moderna investing up to $500 million to produce up to 500 million doses each year for the African... 
From Moderna, Inc.
Via AccessWire
Moderna Announces Establishment of Enterprise Solutions Hub in Atlanta, Georgia
The Americas Enterprise Solutions Hub will support the U.S., Canada and Latin America and is in addition to Moderna's International Enterprise Solutions Hub in Warsaw, Poland Atlanta selected due to... 
From Moderna, Inc.
Via AccessWire
Moderna to Present at Upcoming Conferences in March 2022
CAMBRIDGE, MA / ACCESSWIRE / March 2, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the... 
From Moderna, Inc.
Via AccessWire
EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for The Use of The Moderna Covid-19 Vaccine in Children (6-11 Years) In the European Union
Announcement follows CHMP's previous decision to adopt a positive opinion recommending marketing authorization for Moderna's COVID-19 vaccine to include adolescents 12 years of age and older.... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Updates
Q4 2021 revenues of $7.2 billion; GAAP net-income of $4.9 billion and GAAP diluted EPS of $11.29 Full year 2021 revenues of $18.5 billion; GAAP net-income of $12.2 billion and GAAP diluted EPS of... 
From Moderna, Inc.
Via AccessWire
Moderna and Thermo Fisher Scientific Announce Long-Term Strategic Collaboration
From Thermo Fisher Scientific Inc. and Moderna, Inc.
Via Business Wire
Moderna Expands Global Footprint Through Commercial Partnership with Adium in Latin America
Moderna has a commercial footprint in 56 countries across the world through direct presence and distributors and plans expansion in ten additional markets in 2022 Moderna also supplies the Company's... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine Candidate, Following Independent Safety Review of Interim Data
Endorsement to proceed given by the independent Data and Safety Monitoring Board based on preliminary Phase 2 safety and tolerability data Moderna expects to enroll approximately 34,000 participants in... 
From Moderna, Inc.
Via AccessWire
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.